{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:14:52Z","timestamp":1759940092718},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1097\/01.jaa.0000471610.61784.da","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T12:08:15Z","timestamp":1445947695000},"page":"40-44","source":"Crossref","is-referenced-by-count":2,"title":["Recognizing and treating Raynaud phenomenon"],"prefix":"10.1097","volume":"28","author":[{"given":"Kristen","family":"Thoelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Maiers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy-Ann","family":"Bondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Covino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"7","key":"R1-7-20210130","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.apmr.2011.01.022","article-title":"Effectiveness of interventions for secondary Raynauds phenomenon: a systematic review.","volume":"92","author":"Huisstede","year":"2011","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"R2-7-20210130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2008.06.004","article-title":"Raynauds phenomenon: pathogenesis and management.","volume":"59","author":"Bakst","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R3-7-20210130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/VHRM.S5255","article-title":"Recent achievements in the management of Raynauds phenomenon.","volume":"6","author":"Baumhakel","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"R4-7-20210130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/VHRM.S4551","article-title":"Advances in the treatment of Raynauds phenomenon.","volume":"6","author":"Levien","year":"2010","journal-title":"Vasc Health Risk Manag"},{"issue":"3","key":"R5-7-20210130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynauds condition score in patients with Raynauds phenomenon in a large randomised controlled clinical trial.","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R6-7-20210130","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1136\/bmj.e289","article-title":"Diagnosis and management of Raynauds phenomenon.","volume":"344","author":"Goundry","year":"2012","journal-title":"BMJ"},{"issue":"10","key":"R7-7-20210130","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynauds phenomenon: systematic review and meta-analysis of randomised trials.","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"R8-7-20210130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/imj.12082","article-title":"Treatment of Raynaud phenomenon in systemic sclerosis.","volume":"43","author":"Sinnathurai","year":"2013","journal-title":"Intern Med J"},{"issue":"6","key":"R9-7-20210130","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.jvs.2013.03.012","article-title":"Current medical and surgical management of Raynauds syndrome.","volume":"57","author":"Landry","year":"2013","journal-title":"J Vasc Surg"},{"issue":"12","key":"R10-7-20210130","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynauds phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial.","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology"},{"issue":"15","key":"R11-7-20210130","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study.","volume":"172","author":"Caglayan","year":"2012","journal-title":"Arch Intern Med"},{"issue":"11","key":"R12-7-20210130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/ard.50.11.800","article-title":"A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynauds phenomenon secondary to connective tissue diseases.","volume":"50","author":"Torley","year":"1991","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"R13-7-20210130","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynauds phenomenon. A randomized, controlled study.","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"R14-7-20210130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00005344-199509000-00007","article-title":"Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynauds phenomenon: the acute vasodilatory effect is not sustained.","volume":"26","author":"Kingma","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"R15-7-20210130","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynauds phenomenon with the selective serotonin reuptake inhibitor fluoxetine.","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"issue":"7","key":"R16-7-20210130","first-page":"CD006687","article-title":"Oral vasodilators for primary Raynauds phenomenon.","author":"Stewart","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"R17-7-20210130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"R18-7-20210130","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynauds phenomenon: a randomized, controlled trial.","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Journal of the American Academy of Physician Assistants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000471610.61784.da","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T18:45:04Z","timestamp":1620931504000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201511000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000471610.61784.da","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}